Fluzoparib: all 79 studies that test it
Page 1 of 1. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Phase 2
- Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingNCT07647653Phase 2
- Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian CancerNot yet recruitingNCT07382713Phase 2
- Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)Not yet recruitingNCT07353437Phase 2
- An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed GlioblastomaNot yet recruitingNCT07047066Phase 2
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingNCT06827717Phase 2
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2
- Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingNCT06552858Phase 2
- Fluzoparib Neoadjuvant Therapy for Ovarian CancerRecruitingNCT06541314Phase 2
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian CancerNot yet recruitingNCT06539091Phase 3
- Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
- Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingNCT06413992Phase 2
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingNCT06255392Phase 3
- Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast CancerNot yet recruitingNCT06254066Phase 2
- Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
- Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT06081595Phase 2
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
- Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
- Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue SarcomaRecruitingNCT05894018Phase 2
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3
- Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingNCT05834582Phase 2
- Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationRecruitingNCT05761470Phase 2
- PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerRecruitingNCT05759546Phase 2
- Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT05753826Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingNCT05576389Phase 2
- Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
- A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersEnrolling by invitationNCT05349409Phase 2
- Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingNCT04518501Phase 1/2
- A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
- PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerActive, not recruitingNCT06612814Phase 3
- SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARCStatus unknownNCT06516445Phase 2
- Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)CompletedNCT05938374Phase 2
- The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.Status unknownNCT05732129Phase 2
- Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast CancerSuspendedNCT05656131Phase 2
- A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult SubjectsCompletedNCT05440006Phase 1
- Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialActive, not recruitingNCT05223582Phase 2
- A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerStatus unknownNCT05170594Phase 2
- Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
- Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney FunctionCompletedNCT05032235Phase 1
- A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT04869488Phase 2
- Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
- A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerCompletedNCT04718740Phase 1
- Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver FunctionCompletedNCT04694365Phase 1
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04691804Phase 3
- A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Status unknownNCT04659785Phase 1/2
- A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent GlioblastomaStatus unknownNCT04552977Phase 2
- Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaCompletedNCT04535687Phase 2
- Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult SubjectsCompletedNCT04521192Phase 1
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
- A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic CancerStatus unknownNCT04425876Phase 1
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
- Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese SubjectsStatus unknownNCT04341077Phase 1
- A Trial of SHR3162 in Healthy Caucasian VolunteersCompletedNCT04333134Phase 1
- A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyTerminatedNCT04300114Phase 3
- A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
- A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic CancerCompletedNCT04228601Phase 1/2
- Effect of Fluconazole on PK of Fluzoparib in Healthy Male SubjectsCompletedNCT04193319Phase 1
- Effect of Omeprazole on PK of Fluzoparib in Healthy Male SubjectsCompletedNCT04108676Phase 1
- A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPCStatus unknownNCT04108247Phase 1
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCTerminatedNCT04102124Phase 2
- A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on FluzoparibCompletedNCT04011124Phase 1
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
- A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer PatientsCompletedNCT03863860Phase 3
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerCompletedNCT03509636Phase 1
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- Food-Effect and Metabolism Study in Healthy SubjectsCompletedNCT03062982Phase 1
- A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
- A Phase I Trial of SHR3162 in Subjects With Advanced Solid TumorsCompletedNCT02759666Phase 1
- A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate CancerCompletedNCT02747342Phase 1
- A Phase I Study of Fluzoparib in Patient With Advanced Solid MalignanciesCompletedNCT02575651Phase 1